The Micro Cap Opportunity

 This morning's top Micro Cap trading ideas include, Salon City, Inc. (OTCBB: SLON), Intrepid Technology & Resources, Inc. (OTCBB: ITRP), Sierra Gold Corp. (OTCPK: SGCP), Geotec, Inc. (OTCPK: GETC), EP MedSystems, Inc. (NASD: EPMD), EntreMed, Inc. (NASD: ENMD).

 ?SALON CITY, INC. (OTCBB: SLON)
Up 25.00% Yesterday

  Detailed Quote: http://finance.yahoo.com/q?s=SLON.BB

 Salon City, Inc., the leading media company for beauty entertainment and the first to brand the genre, publishes Salon City magazine, where Life is Beautiful(SM). It is distributed nationally by Time Warner Retail, a Time Warner Company (NYSE: TWX), and internationally by Kable Distribution Services, an AmRep company (NYSE: AXR), in over 30 countries. For information about SCI, visit www.saloncity.com or e-mail info@saloncity.com.

 Recent SLON News:

  April 9, 2008 - Salon City Premiers Latest Webisode Webisode of Hollywood CeleBeauty

 BEVERLY HILLS, CA -- (MARKET WIRE) -- 04/09/08 -- Salon City, Inc. (OTCBB: SLON), the first publicly traded media company to brand its unique content of beauty entertainment to consumers, announced today the debut of its first webisode of 2008. Hollywood CeleBeauty, SCI's infotainment web series, covers the worlds of beauty, fashion, glamour, and celebrity lifestyle. The program is hosted by E! Online personality Christina Gibson, and is now playing at www.saloncity.com.

The series was developed, and is produced, by Hollywood-based production company, matrixx. The company's branded entertainment and product integration skills were utilized to organically embed sponsor information within the show. "The Hollywood CeleBeauty pilot, which aired last winter, received rave responses from viewers," noted matrixx producer Kyle Wiebalk.

According to SCI president and CEO Steven Casciola, the pilot webisode triggered an immediate jump in site traffic, as well as e-mail opt-ins and consumer requests for information from integrated sponsors such as Warren Tricomi and ABS by Allen Schwartz. The new webisode features two new integrations: Great Lengths USA, which was shot at celebrity stylist Kim Vo's hair salon, B2V, in West Hollywood, CA, and COBY Electronics, which includes an MP3 player segment first shot on a green screen sound stage and then digitally created in the matrixx post production facility.

"We're in discussions now with advertisers, sponsors and distributors from across the country to be integrated into planned future shoots," said Casciola. "And for the first time, we're tapping into the demand for cross-promotional packaging, consisting of a multi-tiered media buy that includes online ads, web series integrations, print magazine advertising, showcased exposure at major Salon City, Inc. events, and more. Hollywood CeleBeauty will be an integral part of the media mix we'll be offering as we continue to broaden our presence in the marketplace."

INTREPID TECHNOLOGY & RESOURCES, INC. (OTCBB: ITRP)
Up 30.00% Yesterday

  Detailed Quote: http://finance.yahoo.com/q?s=ITRP.BB

IDAHO FALLS, Idaho, April 9, 2008 /PRNewswire-FirstCall/ -- The Board of Directors of Intrepid Technology and Resources, Inc. (OTC Bulletin Board: ITRP), a renewable biogas alternate energy and soil amendment company, has appointed Mr. Jack Haffey, formerly Executive Vice President and Chief Operating Officer of Montana Power, to the position of Chief Executive Officer of the company.

Mr. Haffey, in accepting the position, states, "When I joined the Intrepid Board, I expressed my belief that Intrepid has a noble purpose, that of making a significant contribution to the environmental well-being of the planet. The Company is now poised to do just that. I am pleased that the Board of Directors has given me the opportunity to join the Intrepid leadership team to help us take our next strategic steps.

"Intrepid's team has proven its concept of processing dairy farm waste, manure, to pipeline quality methane (natural gas), with an important by-product of soil-enriching horticultural fiber. It has also demonstrated that bio-Methane and digested fiber can be sold commercially to end users. Now Intrepid is prepared to take the next step in its long term strategic plan, that of associating with a strategic partner. Intrepid's know how, its intellectual capital, will be joined with the strength of a partner who has capital funds and a shared commitment to producing value in the renewable resources, environmental health sector of the nation and the planet.

"We have a number of potential strategic partners with whom we are now talking, and each one is strongly committed to environmental clean-up and each one has significant financial strength to be a perfect partner for Intrepid. With a partnership in place in the near future, we intend to begin a major manure-to-methane project in Idaho, with the Dairy Farm sector as partners. We will then add other areas as we succeed here in Idaho.

"We have much work to do, and I look forward to working with the Intrepid Team and its Board in this infant industry that is about to blossom."

Lynn Smith, Board Chairman, in expressing his enthusiasm for the vision and energy Mr. Haffey brings to the team, stated, "Jack is the right man at the right time. His executive credentials in the energy and power sector combined with his strong business background are exactly what we need to lift the company to the next level. We are both fortunate and delighted to have him assume the responsibilities of Chief Executive Officer."

Recent ITRP News:

  April 9, 2008 - Intrepid Announces New CEO

IDAHO FALLS, Idaho, April 9, 2008 /PRNewswire-FirstCall/ -- The Board of Directors of Intrepid Technology and Resources, Inc. (OTC Bulletin Board: ITRP), a renewable biogas alternate energy and soil amendment company, has appointed Mr. Jack Haffey, formerly Executive Vice President and Chief Operating Officer of Montana Power, to the position of Chief Executive Officer of the company.

Mr. Haffey, in accepting the position, states, "When I joined the Intrepid Board, I expressed my belief that Intrepid has a noble purpose, that of making a significant contribution to the environmental well-being of the planet. The Company is now poised to do just that. I am pleased that the Board of Directors has given me the opportunity to join the Intrepid leadership team to help us take our next strategic steps.

"Intrepid's team has proven its concept of processing dairy farm waste, manure, to pipeline quality methane (natural gas), with an important by-product of soil-enriching horticultural fiber. It has also demonstrated that bio-Methane and digested fiber can be sold commercially to end users. Now Intrepid is prepared to take the next step in its long term strategic plan, that of associating with a strategic partner. Intrepid's know how, its intellectual capital, will be joined with the strength of a partner who has capital funds and a shared commitment to producing value in the renewable resources, environmental health sector of the nation and the planet.

"We have a number of potential strategic partners with whom we are now talking, and each one is strongly committed to environmental clean-up and each one has significant financial strength to be a perfect partner for Intrepid. With a partnership in place in the near future, we intend to begin a major manure-to-methane project in Idaho, with the Dairy Farm sector as partners. We will then add other areas as we succeed here in Idaho.

"We have much work to do, and I look forward to working with the Intrepid Team and its Board in this infant industry that is about to blossom."

Lynn Smith, Board Chairman, in expressing his enthusiasm for the vision and energy Mr. Haffey brings to the team, stated, "Jack is the right man at the right time. His executive credentials in the energy and power sector combined with his strong business background are exactly what we need to lift the company to the next level. We are both fortunate and delighted to have him assume the responsibilities of Chief Executive Officer."

SIERRA GOLD CORP. (OTCPK: SGCP)
Up 0.00% Yesterday

  Detailed Quote: http://finance.yahoo.com/q?s=SGCP.PK

Sierra Gold is engaged in the exploration and development of gold properties in West Africa. The greenstone belt of West Africa has had a long history of gold mining and prospecting. The region has been one of the fastest gold producing areas worldwide. Sierra Leone's neighbors, Guinea and Mali, are some of the largest gold producers in all of Africa.

Recent SGCP News:

  April 9, 2008 - Sierra Gold Corp. Announces March Gold Production From Joint Venture Property

 TORONTO, April 9, 2008 (PRIME NEWSWIRE) -- Sierra Gold Corp. (Pink Sheets:SGCP) today announced that production from it's initial joint venture partner resulted in slightly in excess of 1 Kg of Alluvial Gold during the month of March 2008. The Company also announced that, in the case of other local Joint Venture partnerships mentioned in an earlier press release, three of the joint venture properties have begun the gravel extraction process and will begin processing extracted ore in the coming weeks. The other three joint ventures anticipate reaching the gold bearing gravels in their areas of operation this week and will commence the extraction process shortly thereafter

Doug Evans, CEO of Sierra Gold, commented, "We are very pleased with how quickly we have been able to expedite the extraction of Gold from our recently announced Joint Venture properties. Our local joint venture partners continue to work hard for us, as we in-turn strive to enrich their lives." He continued, "We anticipate that as the other three joint venture properties come on line and begin producing in the coming weeks the Company will have meaningful production data to release to shareholders once production is in full swing on these properties."

Sierra Gold is currently in the process of updating and reformatting its Web site and has posted some current pictures of JV gold and local activities. To view the pictures, please visit www.sierragoldcorp.com

GEOTEC, INC. (OTCPK: GETC)
Up 21.43% Yesterday

  Detailed Quote: http://finance.yahoo.com/q?s=GETC.PK

Green Energy Technology Company. Geotec has operations in the United States and Argentina and utilizes proteins and enzyme technology to chemically convert hydrocarbons to commercially higher value coal. The technologies are also used to purify hydrocarbons, such as coal or oil, of heavy metals and other contaminants such as sulfur, arsenic and mercury to prevent or correct pollution in the air, water or soils. In addition, hydrocarbon contaminated soils can be re-vegetated and re-forested.

Recent GETC News:

  April 9, 2008 - Geotec, Inc. Files With SEC Its Master Development Agreement With TTI Technologies, Inc. for 10 Coal Sites

  DELRAY BEACH, FL -- (MARKET WIRE) -- 04/09/08 -- Geotec, Inc. (PINKSHEETS: GETC) confirmed today that it has filed with the Securities and Exchange Commission an 8K regarding a Master Development Agreement with TTI Technologies, Inc. Geotec, Inc. entered into a Master Development Agreement with TTI Technologies, Inc. of Omaha, Nebraska regarding further development of Geotec's proprietary enzyme/protein technology. The Parties contemplate that the Technology will be utilized in connection with bio-refinery units for the recovery of saleable coal or any other substance recovered from a designated site that creates revenue from the sale of gob, culm, lignite, or other lower grade or dirty coals or carbon fly ash and for the remediation of soils. Each Facility will be established to process 20 million tons of coal.

The Agreement is for a term of ten (10) years and contemplates two separate scenarios involving the construction and operation of Facilities. For a period of 12 months following the date of the Agreement, regarding projects identified and proposed by Geotec, TTI will advise and assist Geotec in the further development of the Process and in the procurement and construction of the initial equipment for a commercial scale Facility. Geotec has granted a right of first refusal to TTI or one of its affiliates (which may be exercised after the initial 12-month term of this Agreement) to render certain management, administrative, operational and support services in connection with the operation of each Facility controlled by Geotec.

Geotec has granted TTI the right to establish at one or more locations selected and acquired by TTI, up to ten (10) projects utilizing Geotec's proprietary Technology and the Process. Under this scenario, Geotec will be paid its production costs for the Technology plus one dollar ($1.00) per ton of saleable product generated from the Process. Additionally, Geotec will receive a portion of the Net Revenues derived from the TTI projects.

In addition to the generation of revenue, the Parties expect that the Process will generate tax credits under Section 45 of the Internal Revenue Code of 1986, as amended. TTI has substantial experience in connection with the monetization or operation of facilities producing in excess of 40 million tons of solid synthetic fuel (from coal) intended to generate tax credits under Section 29 (now Section 45K) of the Internal Revenue Code.

The Agreement references two related agreements, the forms of which are attached as exhibits to the Agreement. These related agreements include an operating agreement and a supply agreement regarding the operation of each Facility by TTI and/or one of its affiliates and the supplying of the Technology to each Facility by Geotec, respectively. The related agreements will be executed by the Parties upon commencement of each project utilizing a Facility and the Process.

EP MEDSYSTEMS, INC. (NASD: EPMD)                                                                    Up 102.84% Yesterday

Detailed Quote: http://finance.yahoo.com/q?s=EPMD

EP MedSystems develops, manufactures and markets a line of products for use in the cardiac rhythm management or electrophysiology market which are used for visualization, diagnosis and treatment of cardiac rhythm disorders. EP MedSystems' EP product line includes the EP-WorkMate(R) computerized electrophysiology workstation, with expansion options to incorporate the NurseMate(TM) Remote Review Charting Station, and the EP-4(TM) Computerized Cardiac Stimulator. In addition, EP MedSystems' intracardiac echo (ultrasound or ICE) ultrasound catheter system, including its ViewFlex(R) intracardiac imaging catheters and ViewMate(R) II ultrasound imaging system, is used for live visualization of devices and anatomy during catheter based procedures in EP and interventional cardiology. Full year 2007 net sales for EP MedSystems were approximately $19 million. For more information, visit EP MedSystems' website at www.EPMedSystems.com

Recent EPMD News:

  April 9, 2008 - St. Jude Medical to Acquire EP MedSystems

 ST. PAUL, Minn. & WEST BERLIN, N.J.--(BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE: STJ) and EP MedSystems, Inc. (NASDAQ: EPMD) announced today that the Boards of Directors of both companies have unanimously approved a definitive merger agreement under which St. Jude Medical will acquire EP MedSystems for approximately $92.1 million.

Terms of the Agreement

Under the terms of the merger agreement, EP MedSystems shareholders will receive $3.00 of consideration for each EP MedSystems share they own, with the option of receiving that amount in cash or St. Jude Medical common stock. The number of shares of St. Jude Medical common stock that EP MedSystems shareholders will receive will be determined based on the average closing price over 10 trading days, ending on the second business day before the transaction closes. The cash and stock elections are subject to pro-ration such that St. Jude Medical will issue 40 percent of the total merger consideration in St. Jude Medical common stock and 60 percent in cash.

In connection with this transaction, St. Jude Medical's Board of Directors has approved an additional stock buyback authorization of $50 million, which increases St. Jude Medical's share repurchase authorization from $250 million to $300 million. The additional buyback authorization will be used to offset the shares issued in this transaction.

The companies anticipate this acquisition will close during the third quarter of 2008. In connection with this transaction, St. Jude Medical will record a special charge for in-process R&D. This acquisition does not change St. Jude Medical's existing guidance for 2008 earnings per share, exclusive of the special charge.

Acceleration of St. Jude Medical's AF Program

Upon completion, this transaction will immediately add two new growth drivers to St. Jude Medical's program for products used in atrial fibrillation (AF) and other electrophysiology (EP) catheterization procedures. This includes the EP-WorkMate(R) computerized electrophysiology workstation with a fully integrated EP-4(TM) Computerized Cardiac Stimulator and expansion options to incorporate the NurseMate(TM) Remote Review Charting Station. The EP-WorkMate(R) platform already enjoys a strong number two share of the global market for EP recording systems in spite of limited sales and marketing resources.

This transaction will also expedite St. Jude Medical's entry into the high-growth intracardiac ultrasound echocardiography (ICE) market with the EP MedSystems ViewMate(R) II intracardiac ultrasound system and the next generation ViewFlex(TM) PLUS ICE catheter scheduled for market release this quarter. This market is growing at an estimated 25 percent to 30 percent per year and includes both electrophysiology and interventional cardiology applications.

"This transaction will accelerate the growth of St. Jude Medical's program to help physicians cure atrial fibrillation," said Daniel J. Starks, chairman, president and chief executive officer of St. Jude Medical. "EP MedSystems' new ClearWave(TM) signal recording technology and its next generation ViewFlex(TM) PLUS ICE catheter will be especially important additions to our AF technology platform."

David Bruce, president and chief executive officer of EP MedSystems, said, "With growth accelerating over the past year, EP MedSystems' products and market position are stronger than they've ever been thanks to the focus and efforts of our employees. This transaction delivers significant shareholder value and enables our key product platforms to benefit from the extensive worldwide distribution, customer support and product development infrastructure of St. Jude Medical. We look forward to working with the St. Jude Medical team toward a seamless combination."

The transaction is subject to certain closing conditions and regulatory approvals, and approval by EP MedSystems shareholders. Following the close of the transaction, Bruce is expected to join St. Jude Medical, and EP MedSystems will become part of the Atrial Fibrillation division of St. Jude Medical.

In connection with the transaction, Gibson, Dunn & Crutcher, LLP is serving as legal counsel for St. Jude Medical. Piper Jaffray & Co. is acting as financial advisor to EP MedSystems, and Morgan, Lewis & Bockius LLP is serving as legal counsel for EP MedSystems.

Earnings Webcast Information

As previously announced, St. Jude Medical will hold a webcast to discuss its first quarter 2008 financial results on Wednesday, April 16, 2008, at 8:00 a.m. CDT. St. Jude Medical will also discuss this transaction at that time. The webcast can be accessed at www.sjm.com

ENTREMED, INC. (NASD: ENMD)
Up 7.13% Yesterday

  Detailed Quote: http://finance.yahoo.com/q?s=ENMD

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission

Recent ENMD News:

  April 9, 2008 - EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

 ROCKVILLE, Md., April 9, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a Phase 1, dose-escalation study for its selective kinase inhibitor, ENMD-2076, in advanced cancer patients. Dr. Wells Messersmith, University of Colorado Cancer Center, will serve as co-principal investigator for the study. Additional centers are expected to join Colorado as study sites this quarter.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a novel, selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to the promotion of cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple preclinical models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular toxicity.

The Phase 1 study will assess safety and tolerability of orally administered ENMD-2076 in refractory cancer patients. In addition, pharmacokinetics will be assessed to determine a dose-dependent response to treatment with ENMD-2076.

Carolyn F. Sidor, M.D., M.B.A., EntreMed's Vice President and Chief Medical Officer, commented on the study, "Commencement of this Phase 1 study marks the achievement of a critical milestone in our clinical development program and further supports our strategy of focusing on orally-administered, small molecule drugs with multiple mechanisms of action. Data from preclinical studies with ENMD-2076 demonstrate its significant antitumor potential as a single agent in a variety of tumor types. Through this Phase 1 study, we expect to not only determine ENMD-2076's safety profile and appropriate Phase 2 dosing schedule, but which tumor types may be better suited for this compound. We plan to initiate a second Phase 1 study in patients with hematological cancers later this year."

James S. Burns, EntreMed President & Chief Executive Officer commented, "ENMD-2076 is an exciting selective kinase inhibitor with potent single agent activity that has induced tumor regression in multiple preclinical models. ENMD-2076, developed internally, is consistent with our focus on investing behind oncology drug candidates with strong single-agent activity and with our continuing interest in selective kinase inhibitors. In parallel with the clinical trial, we will seek a pharmaceutical or biotech partner to help accelerate the development of our novel selective kinase inhibitor."